Teva Pharmaceutical Industries recently reported third-quarter 2025 earnings that exceeded analysts’ expectations, advanced ...

Amneal wins FDA approval for two denosumab biosimilars, expanding lower-cost treatment options for bone loss and cancer patients.

FDA approves new denosumab biosimilars, enhancing treatment options for osteoporosis and bone metastases while driving ...

Amneal Pharmaceuticals has just seen its fair value estimate nudged to US$14.00 from US$13.80, a small but meaningful reset that ties directly to how the latest quarterly numbers stack up against ...

In today’s Pharma Pulse, the FDA clears new denosumab biosimilars for osteoporosis and cancer-related bone loss, while ...

Drug major Dr Reddy's Laboratories Limited's wholly owned subsidiary, Dr. Reddy's Laboratories SA, Switzerland, has received ...

Dr Reddy's Laboratories announced that its wholly owned subsidiary, Dr. Reddy's Laboratories SA, Switzerland, has received a Complete Response Letter (CRL) from the USFDA for its Biologics License ...

Dr Reddy’s Laboratories ( ($RDY) ) just unveiled an update. On December 31, 2025, Dr. Reddy’s Laboratories disclosed that its wholly owned Swiss ...

AVT03 is a proposed biosimilar candidate to Prolia and Xgeva, developed by Alvotech hf. The application was submitted by Dr ...

From a price-performance perspective, BMY has fetched slightly better returns than AMGN in the past six months. Shares of AMGN have gained 13.5%, while those of BMY have gained 13.9%. The industry has ...

Bridgewater: Amneal Pharma and mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, ...

Amneal Pharma receives US FDA approval for denosumab biosimilars Prolia and Xgeva: Bridgewater, New Jersey Friday, December 26, 2025, 16:00 Hrs [IST] Bridgewater headquartered Amn ...